A pharmaceutical composition comprising a thiazolidinedione such as Compound (I) metformin hydrochloride and a pharmaceutically acceptable carrier wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.

A pharmaceutical composition comprising a thiazolidinedione such as Compound (I) metformin hydrochloride and a pharmaceutically acceptable carrier wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.

The use of a compound of formula (A) or a bioprecursor or a pharmaceutically acceptable salt phosphate ester and/or acyl derivative of either of the foregoing in the manufacture of a medicament for use in the treatment (including prophylaxis) of HHV-8 infection.

A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxetine.

A pharmaceutical composition comprising a thiazolidinedione such as Compound (I) metformin hydrochloride and a pharmaceutically acceptable carrier wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.

A pharmaceutical composition comprising a thiazolidinedione such as Compound (I) metformin hydrochloride and a pharmaceutically acceptable carrier wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.

A pharmaceutical composition comprising a thiazolidinedione such as Compound (I) metformin hydrochloride and a pharmaceutically acceptable carrier wherein the thiazolidinedione and metformin hydrochloride are each dispersed within its own pharmaceutically acceptable carrier in the pharmaceutical composition and the use of such a composition in medicine.

A process for the preparation of a salt of clavulanic acid wherein clavulanic acid in solution in a wholly or partly water-imiscibl e organic solvent is contacted in a region of high turbulence and/or shear stress with a salt precursor compound to form a solution o f the salt of clavulanic acid in an aqueous phase then the organic solvent and aqueous phases are physically separated during a separatio n step followed by a further processing step in which the said salt of clavulanic acid is isolat...

A back extraction process in which beta-lactam antibiotics or clavulanic acid is extracted from an organic solvent phase into an aqeous medium phase using a mixing region in which the phases are mixed rapidly under high turbulence and shear stress.

A method for the treatment and/or prophylaxis of diabetes mellitus conditio ns associated with diabetes mellitus and certain complications thereof in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanide antihyperglycaemic agent to a mamm al in need thereof and a pharmaceutical composition comprising an insulin sensitiser and a biguanide antihyperglycaemic agent.